Supriya Lifescience Limited (SUPRIYA) - Total Liabilities
Based on the latest financial reports, Supriya Lifescience Limited (SUPRIYA) has total liabilities worth Rs1.21 Billion INR (≈ $13.10 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Supriya Lifescience Limited - Total Liabilities Trend (2018–2025)
This chart illustrates how Supriya Lifescience Limited's total liabilities have evolved over time, based on quarterly financial data. See SUPRIYA current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Supriya Lifescience Limited Competitors by Total Liabilities
The table below lists competitors of Supriya Lifescience Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Seneca Foods Corp A
NASDAQ:SENEA
|
USA | $508.64 Million |
|
Argo Properties NV
TA:ARGO
|
Israel | ILA419.95 Million |
|
BGT Group Co. Ltd.
SHE:300774
|
China | CN¥762.53 Million |
|
Shenzhen Comix Group Co Ltd
SHE:002301
|
China | CN¥4.96 Billion |
|
Shenzhen Chuangyitong Technology Co.Ltd.
SHE:300991
|
China | CN¥610.98 Million |
|
Sagicor Financial Company
TO:SFC
|
Canada | CA$23.66 Billion |
|
Metro Healthcare Indonesia
JK:CARE
|
Indonesia | Rp1.17 Trillion |
|
Winnebago Industries Inc
NYSE:WGO
|
USA | $816.40 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Supriya Lifescience Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SUPRIYA company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Supriya Lifescience Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Supriya Lifescience Limited (2018–2025)
The table below shows the annual total liabilities of Supriya Lifescience Limited from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs1.16 Billion ≈ $12.50 Million |
+9.15% |
| 2024-03-31 | Rs1.06 Billion ≈ $11.45 Million |
-12.37% |
| 2023-03-31 | Rs1.21 Billion ≈ $13.07 Million |
+1.46% |
| 2022-03-31 | Rs1.19 Billion ≈ $12.88 Million |
-32.68% |
| 2021-03-31 | Rs1.77 Billion ≈ $19.13 Million |
-5.53% |
| 2020-03-31 | Rs1.87 Billion ≈ $20.25 Million |
+17.57% |
| 2019-03-31 | Rs1.59 Billion ≈ $17.22 Million |
-16.50% |
| 2018-03-31 | Rs1.91 Billion ≈ $20.63 Million |
-- |
About Supriya Lifescience Limited
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti"hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary… Read more